Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
Table 3
Clinical responses in the Rituximab and Placebo groups, and response durations for patients with significant responses, derived from self-reported Fatigue scores during 12 months follow-up.